A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands

To gain insight into current treatment and barriers to optimal treatment for high disease activity relapsing remitting multiple sclerosis (MS) in the Netherlands. A two-round Delphi panel using an online questionnaire was conducted. Seven MS neurologists from diverse locations in the Netherlands wer...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2021-02, Vol.10 (2), p.93-100
Main Authors: Michels, Renée E, Peters, Michel L, Schiffers, Krijn Mh, Bouma, Paul A, Hengstman, Gerald Id, van Munster, Caspar Ep, Zeinstra, Esther, Voer, Gert De, Krol, Marieke
Format: Article
Language:English
Subjects:
Delphi panel
disease modifying therapy
Multiple sclerosis
Patients
Questionnaires
reimbursement
relapsing remitting multiple sclerosis
the Netherlands
treatment pathway
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To gain insight into current treatment and barriers to optimal treatment for high disease activity relapsing remitting multiple sclerosis (MS) in the Netherlands. A two-round Delphi panel using an online questionnaire was conducted. Seven MS neurologists from diverse locations in the Netherlands were invited to participate. Out of the seven MS neurologists, five completed both questionnaire rounds. Effectiveness and side effects along with patient’s lesion load were the most important factors for choosing a disease modifying therapy (DMTs). Respondents felt restricted to optimally treat their patients due to reimbursement restrictions for certain disease modifying therapies, although agreed that satisfactory treatment options are currently available. The answers show consensus between the participating MS neurologists with high certainty of answers.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2020-0140